“In honor of being too sick to get out of bed today, resharing the piece I wrote for my one year anniversary of living with Long COVID. I tried to describe what it’s like to become homebound and have to learn to find joy here.”
Patients react to Trump’s closure of the long-COVID office: ‘I am horrified to think about care becoming less accessible’
“An estimated 23 million people in the U.S. have long COVID, but their care and treatment needs have long been neglected, and under President Donald Trump, the situation is even more dire. “
An estimated 23 million people in the U.S. have long COVID, but their care and treatment needs have long been neglected, and under President Donald Trump, the situation is even more dire.
Excess weight is associated with neurological and neuropsychiatric symptoms in post-COVID-19 condition: A systematic review and meta-analysis
A new study published Wednesday in PLOS has identified neurological and neuropsychiatric symptoms — headaches, vertigo, sleep problems, smell and taste disorder, depression — as more likely to occur in people with what the authors term “excess weight” based on BMI.
Clinical trial underway to assess effectiveness and safety of potential Long Covid treatment
“A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid, the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced today.”
A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid, the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced today.
Analysis: Long-COVID burden reduced 7 months after acute infection
“A new study conducted in Italy reveals a reduction in long-COVID burden 7 months following the acute phase. The study, published in BMC Infectious Diseases, also shows that one-third of patients experienced long-lasting symptoms during almost 2 years of follow-up.”
A new study conducted in Italy reveals a reduction in long-COVID burden 7 months following the acute phase. The study, published in BMC Infectious Diseases, also shows that one-third of patients experienced long-lasting symptoms during almost 2 years of follow-up.
Digital Long Covid Communities-Shaping Diagnoses, Treatment Strategies and Modes of Expertise - PubMed
The study highlights three major themes, namely: users seeking commonalities in experienced symptoms, interpatient tinkering as a form of biohacking conceptualised as an epistemological process, and negotiating expertise.
Long COVID prevalence and risk factors in adults residing in middle- and high-income countries: secondary analysis of the multinational Anti-Coronavirus Therapies (ACT) trials
Long COVID prevalence and risk factors in adults residing in middle- and high-income countries: secondary analysis of the multinational Anti-Coronavirus Therapies (ACT) trials
Long COVID prevalence and risk factors in adults residing in middle- and high-income countries: secondary analysis of the multinational Anti-Coronavirus Therapies (ACT) trials
Studies: 1 in 7 US working-age adults report long COVID, with heaviest burden on the poor | CIDRAP
“An age- and sex-adjusted model of 2022 data from 154,430 participants estimated that those vaccinated against COVID-19 had a 14% lower risk of protracted symptoms than their unvaccinated peers, but a fully adjusted model found no difference in risk. In comparison, a fully adjusted model of 2023 data from 220,664 respondents found a higher risk of long COVID among the vaccinated than the unvaccinated.”
